💉 Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
Ozempic. Wegovy. Mounjaro. Zepbound. If you haven’t heard of GLP-1 drugs by now, you almost certainly know someone who’s taking one.
These medications have gone from niche diabetes treatments to the most talked-about drugs of the decade — with millions of people in the US, UK, Canada, and Australia now using them for weight loss. But what do they actually do to your body? Do they really work? And what are the risks nobody’s talking about?
Here’s a comprehensive, medically grounded guide to GLP-1 drugs in 2026 — without the hype. For broader context on 2026’s top health trends, see our guide to metabolic flexibility: the science of losing weight without dieting.
What Are GLP-1 Drugs?
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the gut after you eat. Its job is to signal your pancreas to release insulin, slow down stomach emptying, signal your brain that you’re full, and reduce the urge to eat.
GLP-1 receptor agonists are medications that mimic these effects, amplifying your body’s natural processes. They were originally developed for type 2 diabetes — but researchers noticed significant weight loss as a side effect. That “happy accident” has made them the dominant weight management intervention of the 2020s.
The Main GLP-1 Drugs: What’s the Difference?
| Drug Name | Active Ingredient | Approved For | How Taken |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Weekly injection |
| Wegovy | Semaglutide (higher dose) | Weight loss (obesity) | Weekly injection or pill |
| Mounjaro | Tirzepatide | Type 2 diabetes | Weekly injection |
| Zepbound | Tirzepatide (same as Mounjaro) | Weight loss (obesity) | Weekly injection |
| Saxenda | Liraglutide | Weight loss | Daily injection |
💡 Key distinction: Ozempic and Wegovy contain the exact same active ingredient (semaglutide) — Wegovy is essentially a higher dose specifically approved for weight loss. The same relationship exists between Mounjaro and Zepbound (both contain tirzepatide).
How Do They Work Inside Your Body?
🧭 In the gut: slowing digestion
GLP-1 drugs delay gastric emptying — food moves more slowly from your stomach to your intestines. You feel full longer after eating, and blood sugar spikes are reduced. This is also the main reason for nausea as a side effect: food is sitting in your stomach for longer than your body is used to.
🥂 In the pancreas: regulating insulin
The drugs stimulate insulin release when blood sugar is high — but crucially, they don’t trigger insulin release when blood sugar is normal. This glucose-dependent action significantly reduces the risk of dangerous hypoglycaemia, making them safer than many older diabetes treatments.
🧠 In the brain: reducing hunger
GLP-1 drugs act on the hypothalamus, the brain region that regulates appetite and hunger cues. Many users describe the “food noise” — the constant background thinking about food — simply going quiet. The precise neural mechanism isn’t fully understood, which is an important consideration for long-term use decisions.
What Results Can You Actually Expect?
15–17%
Average body weight lost on Wegovy (semaglutide) in clinical trials over 68 weeks
20%+
Weight loss seen in some Zepbound (tirzepatide) trials — the newer dual-action drug
83%
of Wegovy trial participants lost 5%+ of starting body weight, vs 31% on diet and exercise alone
For comparison, older weight loss medications typically produced 5–10% weight loss. GLP-1 drugs have genuinely raised the bar. That said, they work best alongside dietary changes and regular exercise — particularly resistance training and Zone 2 cardio to preserve muscle mass during weight loss.
Side Effects: What to Expect
Common and generally manageable
Gastrointestinal symptoms are by far the most frequently reported side effects. They’re typically worst at the start of treatment and when doses are increased, and often improve over time:
- Nausea (affects up to 40–50% of users initially — the most common)
- Constipation
- Vomiting
- Diarrhoea
- Stomach cramps or reflux
Nausea can be reduced by avoiding strong smells, eating smaller and more frequent meals, and adequate protein intake. Many users find symptoms diminish significantly after the first few weeks.
“Ozempic Face” — the cosmetic side effect
💡 Rapid weight loss from any cause can cause facial changes: a hollowed appearance around the cheeks and eyes, increased wrinkling, and sagging skin. The term “Ozempic face” is misleading — it applies to any rapid weight loss, not just this drug. Losing weight more gradually (via a lower dose) reduces this effect. Adequate protein and resistance training also help preserve facial and body composition.
Rare but serious risks
| Risk | What You Need to Know |
|---|---|
| Pancreatitis | Possible elevated risk; recent data suggests lower than originally thought. Symptoms: severe abdominal pain, nausea, vomiting. |
| Gallbladder issues | Rapid weight loss (from any cause) increases gallstone and gallbladder inflammation risk. |
| Thyroid tumours | Flagged in animal studies; not confirmed in humans. Not recommended for anyone with a history of medullary thyroid cancer. |
| Surgery risk | Must stop at least 1 week before general anaesthesia due to delayed gastric emptying. Many hospitals now have formal policies on this. |
| Muscle loss | Can occur with rapid weight loss. Mitigated by adequate protein (1.2–1.6g/kg) and resistance training. |
⚠️ The Critical Thing Most Articles Don’t Tell You: The Weight Returns When You Stop
Most people regain weight when they stop taking GLP-1 drugs. Clinical studies confirm this — participants who stopped Wegovy regained most of the weight they had lost. As one Columbia University bariatric surgeon put it: “If the drug isn’t there, the disease is.”
GLP-1 drugs manage obesity the way blood pressure medication manages hypertension — stop the medication and the condition returns. This means they’re generally considered long-term or lifelong treatments, not short-term tools. The cost implications are significant.
How Much Do They Cost?
🇺🇸 United States
- Ozempic: ~$1,200/month without insurance
- Wegovy: ~$1,600/month without insurance
- Foundayo (GoodRx): from ~$149/month
- Zepbound (GoodRx): from ~$299/month
Insurance covers diabetes versions (Ozempic, Mounjaro) more readily than weight loss versions (Wegovy, Zepbound). Coverage varies significantly by plan.
🇬🇧 United Kingdom
Wegovy is available on the NHS through specialist weight management services in England. Access remains limited; criteria require BMI 35+ (or 30+ for certain ethnic backgrounds) plus at least one weight-related condition. Scotland, Wales, and Northern Ireland availability varies.
🇨🇦🇦🇺 Canada & Australia
Coverage varies by province, territory, and insurance plan in both countries. Out-of-pocket costs are comparable to the US without coverage. Check with your provincial health authority or insurer for current status.
⚠️ Warning: Compounded GLP-1s. The FDA has resolved the previous drug shortage and is now taking action against mass-marketed compounded (non-FDA-approved) versions of semaglutide. These are not tested for safety, efficacy, or purity. Avoid them.
Beyond Weight Loss: What Else Can These Drugs Do?
- Heart health: Ozempic and Wegovy have both shown reduced risk of heart attack, stroke, and cardiovascular death in people with relevant conditions. This is one of the most well-established benefits beyond glycaemic control.
- Brain health: Early research suggests GLP-1 drugs may help protect against neurodegenerative diseases like Alzheimer’s and may slow cognitive decline — though this remains investigational.
- Addiction treatment: Emerging research is exploring whether GLP-1 mechanisms might reduce cravings for alcohol, nicotine, and opioids, given their effect on the brain’s reward centres.
- Sleep apnoea: Weight loss improves sleep apnoea, and trials are underway exploring direct drug effects on this condition. For evidence-based approaches to sleep optimisation, see our guide to science-backed sleep hacks for 2026.
GLP-1 Drugs vs. Lifestyle: The Evidence-Based Approach
GLP-1 drugs are most effective when combined with lifestyle change, not instead of it. The clinical trials that showed 15–17% weight loss were conducted with dietary changes and exercise programmes alongside the medication. If you’re looking at the evidence-based lifestyle foundation, our guides to losing belly fat with Zone 2 and HIIT and metabolic flexibility cover the science in detail.
📚 Related Reading
- → How to Lose Belly Fat in 2026: Why Zone 2 and HIIT Are the New Gold Standard
- → Metabolic Flexibility: The Secret to Losing Weight Without Dieting
- → 10 Science-Backed Sleep Hacks for the Always-On Professional
- → The 2026 Gut Health Protocol: Best Foods for a Diverse Microbiome
- → The Longevity Habit Guide: Small Daily Shifts to Increase Your Healthspan
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both contain the same active ingredient, semaglutide. Ozempic is approved for type 2 diabetes at a lower dose. Wegovy is a higher-dose version specifically approved for weight management in people with obesity or overweight with health complications. You don’t need a diabetes diagnosis to be prescribed Wegovy.
How much weight will I lose on Ozempic or Wegovy?
Clinical trials show an average of 15–17% of starting body weight on Wegovy over 68 weeks, combined with lifestyle changes. Tirzepatide (Zepbound) may produce slightly greater average weight loss. Individual results vary considerably. Stopping the medication typically results in weight regain.
Can I get GLP-1 drugs on the NHS (UK)?
Wegovy is available on the NHS in England through specialist weight management services. Access is currently limited; criteria include BMI 35+ (or 30+ for certain ethnic groups) plus at least one weight-related condition. Availability varies across Scotland, Wales, and Northern Ireland.
Do GLP-1 drugs cause muscle loss?
Muscle loss can occur with rapid weight loss from any cause, including GLP-1 drugs. Mitigate this with adequate protein intake (1.2–1.6g per kg of bodyweight) and regular resistance exercise. This is why these drugs work best as part of a broader lifestyle change, not in isolation.
Will I regain weight when I stop taking GLP-1 drugs?
Most people do regain weight after stopping, as confirmed by clinical trial follow-up data. Obesity is a chronic medical condition — GLP-1 drugs treat it, they don’t cure it. Long-term or lifelong use is typically needed to maintain results.
Are there long-term side effects?
Long-term safety data is still accumulating. Known long-term risks include gallbladder issues and muscle loss if protein intake is insufficient. The thyroid cancer signal seen in animals has not been confirmed in long-term human studies. Discuss long-term treatment plans with your prescribing physician.
Sources: Columbia University Medical Center, Harvard Health Publishing, UCLA Health, Touro College of Pharmacy, Mayo Clinic, Johns Hopkins Medicine, GoodRx, FDA Drug Approvals Database.
